| Drug Name |
Selinexor |
| Drug ID |
BADD_D02493 |
| Description |
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. It is currently approved for the treatment of multiple myeloma, a cancer which forms from antibody-producing plasma cells.[L7117,L7120] This condition is typically treated with high dose [bortezomib] and dexamethasone chemotherapy followed by autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant.[L7123] Selinexor was approved by the FDA in June 2019. It was granted fast track and orphan designation as well as accelerated approval based on single arm, open label trial data. The Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) trial is planned to finish in 2020.[L7126] |
| Indications and Usage |
Selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone.[label] Patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX66 |
| DrugBank ID |
DB11942
|
| KEGG ID |
D11222
|
| MeSH ID |
C585161
|
| PubChem ID |
71481097
|
| TTD Drug ID |
D00LNW
|
| NDC Product Code |
11014-0455; 72237-101; 72237-102; 72237-104; 72237-103; 11014-0393; 62009-1911; 11014-0456; 11014-0454 |
| UNII |
31TZ62FO8F
|
| Synonyms |
selinexor | Xpovio | KPT-330 |
